Trump administration
Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices
Lilly; Novo Nordisk; White House; obesity drug prices; Medicare coverage; GLP-1 medications; Trump administration; Zepbound; Wegovy
Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027
Cigna; drug rebates; pharmacy benefit manager; Evernorth; Express Scripts; upfront discounts; brand-name prescriptions; pharmacy reimbursement; Trump administration; drug pricing
White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations
most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca
White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement
most favored nation; drug pricing; White House; executive order; pharmaceutical companies; Medicaid; Medicare; drug manufacturers; Trump administration; prescription drug costs; deadline; pharma concessions
Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift
pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority
Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted
15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation
Tariffs and MFN Policy Power a Broad, Confusing Pharma War
tariffs; Most Favored Nation (MFN) policy; prescription drug pricing; pharmaceutical industry; Trump administration; drug manufacturing; onshoring; Medicaid; pharma innovation
FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing
FDA PreCheck; domestic drug manufacturing; pharmaceutical supply chain; API; regulatory streamlining; facility construction; national security; Trump administration
Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats
Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA
Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment
Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance